JMP Securities Sticks to Their Buy Rating for Blueprint Medicines (BPMC)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Blueprint Medicines (BPMCResearch Report), with a price target of $152.00. The company’s shares closed last Monday at $44.02.

According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.3% and a 29.0% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $86.25, an 88.4% upside from current levels. In a report issued on June 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $117.86 and a one-year low of $47.71. Currently, Blueprint Medicines has an average volume of 691.2K.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Last month, Nicholas Lydon, a Director at BPMC bought 10,909 shares for a total of $213,053.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed